Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives

In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program:  https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.